US/UK/Canada

Share

Pick a time period -
Tags ( Active)

DBP’s scientific paper about MGMT and Temodex is in PubMed

Double Bond Pharmaceutical’s pilot study on whether MGMT, the well-known biomarker in glioma treatment, can affect the overall survival of brain cancer patients treated with Temodex is now available online at PubMed as “ahead of print”. The paper was, as earlier reported, peer-reviewed by an expert panel and thereafter accepted for publication in Neoplasma. The hard copy of the article in the journal will be issued in the beginning of 2019. "The study results provide an important insight into the potential magnitude of the therapeutic value of Temodex and SI053", - says Igor Lokot, CEO

Double Bond Pharmaceutical expands the cooperation with Alexandrov Cancer Centre to identify biomarkers for Temodex

As previously described, DBP has recently started an extensive partnership agreement with N. N. Alexandrov National Centre of Belarus on Temodex. Now the cooperation is deepened further and includes the identification of potential biomarkers for Temodex. "Biomarkers are absolutely central in the development of modern drugs, especially as so-called personalized medicine becomes increasingly vital in the pharmaceutical world. We see a great potential and opportunities in effective development of biomarkers, - says Igor Lokot, CEO of DBP. - This ensures further the therapeutic value of

Promising results for Temodex, drug candidate against brain cancer, after completion of the first MGMT study

Preliminary results indicate that there is no significant difference in survival between MGMT methylation-positive and negative patients treated with Temodex, and that all patients who received Temodex had a significantly better survival than the control group when both DNA and protein data for MGMT were taken into account. This result will later this year be presented at scientific meetings and in scientific journals. Further studies on a larger group of patients are scheduled to start shortly. "MGMT status permits to distinguish patients who respond well or respond poorly to standard-

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe